Arginine Vasopressin and Posterior Reversible Encephalopathy Syndrome Pathophysiology: the Missing Link?

Mol Neurobiol. 2019 Oct;56(10):6792-6806. doi: 10.1007/s12035-019-1553-y. Epub 2019 Mar 28.

Abstract

Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological entity characterized by a typical brain edema. Its pathogenesis is still debated through hypoperfusion and hyperperfusion theories, which have many limitations. As PRES occurs almost exclusively in clinical situations with arginine vasopressin (AVP) hypersecretion, such as eclampsia and sepsis, we hypothesize that AVP plays a central pathophysiologic role. In this review, we discuss the genesis of PRES and its symptoms through this novel approach. We theorize that AVP axis stimulation precipitates PRES development through an increase in AVP secretion or AVP receptor density. Activation of vasopressin V1a receptors leads to cerebral vasoconstriction, causing endothelial dysfunction and cerebral ischemia. This promotes cytotoxic edema through hydromineral transglial flux dysfunction and may increase endothelial permeability, leading to subsequent vasogenic brain edema. If our hypothesis is confirmed, it opens new perspectives for better patient monitoring and therapies targeting the AVP axis in PRES.

Keywords: Antidiuretic hormone; Blood-brain barrier; Hypertensive encephalopathy; Leukoencephalopathy syndrome; Neurological adverse drug reactions.

Publication types

  • Review

MeSH terms

  • Animals
  • Arginine Vasopressin / metabolism*
  • Biomarkers / metabolism
  • Comorbidity
  • Disease Susceptibility
  • Humans
  • Models, Biological
  • Posterior Leukoencephalopathy Syndrome / pathology
  • Posterior Leukoencephalopathy Syndrome / physiopathology*

Substances

  • Biomarkers
  • Arginine Vasopressin